261 related articles for article (PubMed ID: 36344420)
1. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Çiftçiler R; Akın MG; Erat Z; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420
[TBL] [Abstract][Full Text] [Related]
2. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
[TBL] [Abstract][Full Text] [Related]
3. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e138-e141. PubMed ID: 38195325
[TBL] [Abstract][Full Text] [Related]
4. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
5. Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia.
Kim E; Hwang EJ; Lee J; Kim DY; Kim JY; Kim DW
Neoplasia; 2022 Oct; 32():100817. PubMed ID: 35878453
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
7. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
8. Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Ureshino H; Kamachi K; Sano H; Okamoto S; Itamura H; Yoshimura M; Katsuya H; Ando T; Kimura S
Hematology; 2022 Dec; 27(1):1171-1175. PubMed ID: 36326484
[TBL] [Abstract][Full Text] [Related]
9. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
11. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
12. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
Elias F; Gebran A; Said C; Beker RV; Ammar W
J Glob Oncol; 2019 Jun; 5():1-7. PubMed ID: 31166826
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).
Mikhaeel S; Atallah E
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):333-339. PubMed ID: 36934065
[TBL] [Abstract][Full Text] [Related]
15. Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
Ureshino H; Kamachi K; Nishioka A; Okamoto S; Katsuya H; Yoshimura M; Kubota Y; Ando T; Kimura S
Hematol Oncol; 2021 Oct; 39(4):549-557. PubMed ID: 34117654
[TBL] [Abstract][Full Text] [Related]
16. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
17. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
19. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
20. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
